|Bid||69.43 x 1100|
|Ask||69.46 x 1000|
|Day's Range||68.93 - 70.28|
|52 Week Range||68.91 - 110.81|
|Beta (3Y Monthly)||1.49|
|PE Ratio (TTM)||19.18|
|Earnings Date||Jan 23, 2019 - Jan 28, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||108.23|
Jim Cramer says a biotechnology stock could launch a recovery if the midterm elections bring a blue wave to Congress.
Last year, Dragonfly pulled in $33 million through a deal with Celgene to develop immuno-oncology drugs that take aim at blood cancer. Dragonfly will get $50 million through an upfront fee in this latest deal, and could earn potential future milestone and royalty payments, as well as other considerations, the company said. Celgene is tapping into Dragonfly’s technology for harnessing the immune system in the fight against cancer.
The Standard & Poor's 500-stock index is on pace for well-below-average gains in 2018. While the 2% improvement year-to-date isn't exactly catastrophic, it is disappointing compared to most expectations for the year, and it has been littered with several shares that have simply been cleaved. But there is a silver lining: This has created a number of deeply discounted stocks to buy. History has shown us that when rates rise, stocks typically decline - at least temporarily. This was the case in 1994, 2006 and last February. The market's latest swoon, caused in part by more upward pressure on interest rates, may be painful, but it too may just be temporary. That's little comfort to owners of numerous stocks that have fallen precipitously off their recent highs. But that is good news for bargain hunters that are looking for battered stock picks to grab up off the ground. Here are 10 deeply discounted stocks to buy - companies that are anywhere from 20% to 50% off of their 52-week highs: SEE ALSO: 101 Best Dividend Stocks to Buy for 2019 and Beyond
Consider Gilead Sciences (GILD) and Celgene (CELG) for example. At recent prices of $70 and $75, they traded at market values that aren’t too far above the value of their operating businesses, according to discounted cash flow analysis by Jefferies biotech analyst Michael Yee and his team. Then add if they fall back to their “free pipeline” stock prices.
NEW YORK, Nov. 14, 2018 /PRNewswire/ -- Lyfebulb, a chronic disease-focused, patient-empowerment platform that connects patients with industry and investors to support user-driven innovation, announced it is joining forces with Celgene (CELG) to launch Addressing Unmet Needs in MS: An Innovation Challenge, to seek new solutions aimed at addressing the daily challenges associated with multiple sclerosis (MS). The Innovation Challenge will take place in May 2019 and will be open to patient entrepreneurs—those who have been affected by MS as either a patient, loved one or support partner—whose companies are helping develop solutions to address an unmet need in multiple sclerosis. The goal of the innovation challenge is to shed light on the endeavors and ideas of patient entrepreneurs while raising awareness about this chronic condition.
Nine companies have majority ‘buy’ ratings, with upside potential of as much as 123%, according to analysts.
Prothena (PRTA) posts narrower-than-expected loss in the third quarter. With the failure of lead drug, NEOD001, the focus is now on its mid-stage candidate, prasinezumab.
US voters have delivered a split verdict in midterm elections for Congress. Democrats regained a majority of seats in the House of Representatives but Republicans have retained control of the Senate, where they are on course for a net gain of at least three seats. Donald Trump boasted at a press conference on Wednesday about how his campaigning paid off for multiple candidates in the midterm elections.
Biogen Inc. (NASDAQ: BIIB) fell alongside the broad market selloff in October, but Biogen stock rallied rebounded when it reported third-quarter results. With BIIB stock price still in value territory at 15 times earnings and 11 times forward earnings, investors should take a closer look at the latest results.
Agios' (AGIO) loss tops estimates in Q3. Its precision medicine Tibsovo's performance in the very first quarter after approval in July leads to a significant year-over-year revenue growth.
bluebird (BLUE) incurs narrower-than-expected Q3 loss on account of higher collaboration revenues. The pipeline progress looks encouraging.
Celgene Corporation (CELG) plans to present at two upcoming investor events where Celgene management will provide an overview of the Company. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Presentations will cover a wide range of blood diseases including multiple myeloma, lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndromes and be